Board of Directors
Shareholdings are correct as at November 25 2019, and are updated every year.
Chairman of the Board, elected 2014. (b. 1950)
Education and experience: Arne Ferstad, bachelor’s degree in Market Economy, CEDEP/INSEAD, has a broad range of experience in the biotech and pharmaceutical industries, including business development and international marketing. He is the CEO and Director of Ankor Consultants Ltd. He was previously in charge of Baxter Healthcare’s business in the Nordic and Benelux countries, President of EMEA Baxter Renal Division, head of Baxter’s bioscience business in Asia and held several senior positions in Baxter R&D. Arne was also General Manager and Vice President at Pharmacia Corporation.
Current assignments: CEO and Chairman of the Board of Ankor Consultants Ltd. Board member of Peptonic Medical AB (publ) and Clinical Laserthermia Systems AB (publ). Chairman of the Board of FluoGuide AS. Chairman of the Board of Panion Animal Health.
Previous assignments: Board member of Cline Scientific AB and Neurovive Pharmaceutical AB (publ). Chairman of the Board of AroCell AB, Medfield Diagnostics AB (publ) and Aggancio Research AB.
Owner and active in the following companies: Ankor Consultants Ltd.
Own and/or related parties’ holdings in the Company: 1 381 432 shares.
Board member, elected 2019. (b. 1958)
Education and experience:Hilde Furberg is an independent consultant and a professional board member. She has broad senior leadership experience, coming from her 35 years in sales, marketing, strategy and general management in Pharma/Biotech. Her experience is in different areas of specialty care, and from small to large global companies. Hilde has worked in companies like Baxter and Genzyme, she was most recently European Head of Rare Diseases for Sanofi Genzyme. In addition to working for Genzyme/Sanofi Genzyme, Hilde has since 2005 been a non-executive director, and board member of BerGenBio, Probi, Pronova, Clavis and Algeta. She is currently an industrial advisor to Investinor and board member of PCI Biotech, Calliditas, Tappin and CoB for Blueprint Genetics. Hilde holds a Master of Science from the University of Oslo (Norway)
Current assignments: Board Member of Calliditas (former Pharmalink AB), PCI Biotech ASA and Tappin.
Previous assignments: Board Member of BerGenBio ASA, Algeta ASA, Clavis, Pronova, Copenhagen Capacity and Probi AB. Chairman of the Board of Blueprint Genetics.
Owner and active in the following companies:
Own and/or related parties’ holdings in the Company: Holds no shares or warrants.
Susana Ayesa Alvarez
Board member, elected 2017. (b. 1970)
Education and experience: Susana Ayesa Alvarez has a Ph.D. in organic chemistry from Stockholm University and a broad range of experience in the pharmaceutical industry. Susana has worked at large pharmaceutical companies such as Pharmacia & Upjohn, Johnson & Johnson, and at major biotech companies such as Medivir AB. She has solid experience in preclinical drug research and pharmaceuticals development, and as a board member has experience in clinical development and commercialisation. She was a board member of Medivir AB (2013–2016), where she has been part of the work of the R&D committee since 2014, and of ACES-SFFS (2014–2017), a non-profit association of Spanish researchers in Sweden. Currently, Susana works as Quality Control and Microbiology Manager at Johnson & Johnson Vision. She has published several scientific articles and is the co-inventor of a large number of medical patents, the majority of which have been granted.
No current assignments.
Previous assignments: Board member of Medivir Aktiebolag.
She has been neither owner nor active in any companies over the last five years.
Own and/or related parties’ holdings in the Company: 4 500 shares.
Board member, elected 2014. (b. 1970)
Education and experience: Peter Nilsson received his M.Sc. in Business Admin and Economics from Lund University and is a certified public accountant who was previously a partner and business area manager of Mazars SET Revisionsbyrå AB. As an auditor, Peter has worked with both owner-managed and public companies, and has conducted exchange audits prior to listing on the NGM stock exchange. He was also director of Corporate Finance at Mazars, focusing on acquisitions and due diligence. Currently, Peter is active as CFO with a focus on strategic and business development in the Rotorbulk Group, also known as Finja.
Current assignments: Board member of PN Finanskonsult AB and Chairman of the Board of Åhus Åkeri AB.
Previous assignments over the last five years: Board member of VA Automotive AB (publ).
Owner and active in the following companies: PN Finanskonsult AB.
Own and/or related parties’ holdings in the Company: 776 002 shares.
Board member, elected 2006. (b. 1966)
Education and experience: Lars Thunberg is a co-founder of CombiGene and was also its Chairman of the Board from August 2013 to October 2014. He has an M.Sc. in Business Administration and Economics from Stockholm University and Lund University.
Current assignments: Board Member of Panion Animal Health AB (former Chairman of the Board) and Board Member of M & L Industriförvaltning.
Previous assignments: Chairman of the Board of Panion Animal Health AB. Board Member of Högskolan Kristianstad Holding AB, Högskolan Kristianstad Uppdrag AB and Estrids Fastighet Hässleholm AB. Chairman of the Board of aXimed AB (publ), aXichem AB (publ), Camito Sweden AB, VA Automation i Hässleholm AB, SwePart verktyg i Tyringe AB, VA International AB, Ningbo Modern Tool and MV HK LTD. Board Member of VA Components i Hässleholm AB, VA Tooling AB, VA Engineering i Hässleholm AB, Hardmesch AB, VA Personal AB.
Owner and active in the following companies: M & L Industriförvaltning.
Own and/or related parties’ holdings in the Company: 4 796 038 shares held via endowment insurance.
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 email@example.com.